Principal Investigator
Stephen Lim, MD
Category
Infectious Disease
Title of Protocol
ACTIV-6: COVID-19 Outpatient randomized Trial to Evaluate Efficacy of Repurposed
Medications.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Principal Investigator
Dahlene Fusco, MD, PhD
Category
Infectious Disease
Title of Protocol
A Phase 2a Randomized Controlled Trial of MIB-626 (β-Nicotinamide
Mononucleotide, NMN) vs. Placebo in Adults with COVID-19 Infection and
Early Acute Kidney Injury.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Principal Investigator
Guy Orangio, MD
Category
Colorectal Surgery
Title of Protocol
ADMIRE-CD II: A Phase III, Randomized, Double-Blind, Parallel Group, Placebo-Controlled,
International, Multicenter Study to Assess Efficacy and Safety of Cx601,
Adult Allogeneic Expanded Adipose-Derived Stem Cells (eASC), for the Treatment
of Complex Perianal Fistula(s) in Patients with Crohn’s Disease
over a Period of 24 Weeks and a Follow-Up Period up to 52.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Principal Investigator
Agustin Garcia, MD
Category
Oncology
Title of Protocol
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib,
INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard
Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial,
Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Category
Oncology - Multiple
Title of Protocol
RECITE: A Phase 3 Randomized Placebo-Controlled Double-Blind Study of Romiplostim
for the Treatment of Chemotherapy-Induced Thrombocytopenia in Patients
Receiving Oxaliplatin-Based Chemotherapy for Treatment of Gastrointestinal,
Pancreatic, or Colorectal Cancer.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Category
Oncology - Multiple
Title of Protocol
A Phase 3 Randomized Placebo-Controlled Double-Blind Study of Romiplostim
for the Treatment of Chemotherapy-Induced Thrombocytopenia in Patients
Receiving Chemotherapy for Treatment of Non-Small Cell Lung Cancer (NSCLC),
Ovarian Cancer, or Breast Cancer.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Principal Investigator
Elizabeth Ellent, MD
Category
Oncology - Lung
Title of Protocol
BGB-A317-A1217-302: A Phase 3, Randomized, Double-Blind Study of BGB-A1217,
an Anti-TIGIT Antibody, in Combination with Tislelizumab Compared to Pembrolizumab
in Patients with Previously Untreated, PD-L1-Selected, and Locally Advanced,
Unresectable, or Metastatic Non-Small Cell Lung Cancer.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Principal Investigator
Augustin Garcia, MD
Category
Oncology - Cervical
Title of Protocol
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using
Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent,
Metastatic, or Persistent Cervical Carcinoma.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Category
Oncology - Esophageal
Title of Protocol
KEYNOTE 975: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
of Pembrolizumab (MK-3475) vs. Placebo in Participants with Esophageal
Carcinoma Receiving Concurrent Definitive Chemoradiotherapy.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Category
Oncology - Colorectal
Title of Protocol
LYNK 003: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy
and Safety of Olaparib Alone or in Combination With Bevacizumab Compared
to Bevacizumab with a Fluoropyrimidine in Participants with Unresectable
or Metastatic Colorectal Cancer who Have Not Progressed Following First-line
Induction.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Category
Oncology - Liver
Title of Protocol
LEAP 012: A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled,
Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902)
with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization
(TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular
Carcinoma.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Category
Oncology - Breast
Title of Protocol
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy
with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer
Followed by Adjuvant Continuation of Atezolizumab or Placebo.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Category
Hematology - Breast
Title of Protocol
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant
Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab
and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected
with a Test Measuring Live Cell HER2 Signaling Transduction.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Category
Oncology - Breast
Title of Protocol
The PROOF Trial: A Phase 3 Multicenter, Open-Label, Randomized, Controlled
Study of Oral Infigratinib vs. Gemcitabine with Cisplatin in Subjects
with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene
Fusions/Translocations.
Brief Description
Additional Information
Research Contact
#
504.702.2440
Principal Investigator
Augustin Garcia, MD
Category
Oncology - Breast
Title of Protocol
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and
Tolerability of SGN-LIV1A in Patients with Metastatic Breast Cancer
Brief Description
Additional Information
Research Contact
#
504.702.2440
Principal Investigator
Brian Boulmay, MD
Category
Oncology - Head and neck
Title of Protocol
NRG-HN009: Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin
Every Three Weeks vs. Radiation with Low-Dose Weekly Cisplatin for Patients
with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
Brief Description
Additional Information
Recruitment Contact
#
504.210-2671
Principal Investigator
Brian Boulmay, MD
Category
Oncology - Anal
Title of Protocol
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab
in Metastatic Anal Cancer Patients.
Brief Description
Additional Information
Recruitment Contact
# #
504.210-2671
Principal Investigator
Agustin Garcia, MD
Category
Oncology
Title of Protocol
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who
Achieve a Pathologic Complete Response.
Brief Description
Additional Information
Recruitment Contact
#
504.210.2671
Principal Investigator
Amelia Jernigan, MD
Category
Oncology - Ovarian
Title of Protocol
A Randomized, Phase III, Two Arm Trial of Paclitaxel/Carboplatin/Maintenance
Letrozole Monotherapy in Patients with State II-IV, Primary Low-Grade
Serous Carcinoma of the Ovary or Peritoneum.
Brief Description
Additional Information
Recruitment Contact
#
504.210.2671
Principal Investigator
Brian Boulmay, MD
Category
Oncology
Title of Protocol
A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected
NSCLC: ALCHEMIST Chemo-IO (ACCIO).
Brief Description
Additional Information
Recruitment Contact
#
504.210.2671
Principal Investigator
Brian Boulmay, MD
Category
Oncology - Skin
Title of Protocol
EA6174; Testing Pembrolizumab versus Observation in Patients with Merkel
Cell Carcinoma after Surgery.
Brief Description
Additional Information
Recruitment Contact
#
504.210.2671
Principal Investigator
Agustin Garcia, MD
Category
Oncology - Breast
Title of Protocol
DRAGONFLY: A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending
Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics,
Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced
or Metastatic Solid Tumors, and Expansion in Selected Indications.
Brief Description
Additional Information
Recruitment Contact
#
504.210.2671
Principal Investigator
Agustin Garcia, MD
Category
Oncology - Breast
Title of Protocol
A011801; The CompassHER2 trials (COMprehensive use of Pathologic Response
ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2
Residual Disease (RD), a double-blinded, phase III randomized trial of
T-DM1 and placebo compared with T-DM1 and tucatinib
Brief Description
Additional Information
Recruitment Contact
#
504.210.2671
Principal Investigator
Michelle Loch, MD
Category
Oncology - Endometrial
Title of Protocol
DARE: A Randomized, Phase II Trial of circulating Tumor DNA guided 2nd
Line Adjuvant Therapy for High Residual Risk, Stage II-III, estrogen Receptor
Positive, HER2 Negative Breast Cancer
Brief Description
Additional Information
Recruitment Contact
#
504.210.1847
Principal Investigator
Navya Nair, MD
Category
Oncology - Endometrial
Title of Protocol
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab
(MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable
Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Brief Description
Additional Information
Recruitment Contact
#
504.210.1847
Principal Investigator
Juzar Ali, MD
Category
Pulmonology
Title of Protocol
ARISE: Validation of Patient Reported Outcome Measures in Participants
With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium
Avium Complex
Brief Description
Additional Information
Recruitment Contact
#
504.568.4634
Principal Investigator
Juzar Ali, MD
Category
Pulmonology
Title of Protocol
ENCORE: A Randomized, Double-Blind, Placebo-Controlled, Active Comparator,
Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome
Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly
Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by
Mycobacterium Avium Complex (MAC)
Brief Description
Additional Information
Recruitment Contact
#
504.568.4634
Principal Investigator
Juzar Ali, MD
Category
Pulmonology
Title of Protocol
ASPEN: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to
Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered
Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis
Brief Description
Additional Information
Recruitment Contact
#
504.568.4634
Principal Investigator
Juzar Ali, MD
Category
Pulmonology
Title of Protocol
Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC)
disease (MAC-CLOFAZ-001)
Brief Description
Additional Information
Recruitment Contact
#
504.568.4634
Principal Investigator
Bennett deBoisblanc, MD
Category
Pulmonology
Title of Protocol
ASTER: Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery.
Brief Description
Additional Information
Recruitment Contact
#
504.568.3451
Principal Investigator
Matthew Lammi, MD
Category
Pulmonology
Title of Protocol
COVID-19 Post-Hospital Thrombosis Prevention Study: A Multicenter, Adaptive,
Prospective, Randomized Trial Evaluating the Efficacy and Safety of Antithrombotic
Strategies in Patients with COVID-19 Following Hospital Discharge
Brief Description
Additional Information
Recruitment Contact
#
504.568.3452
Principal Investigator
Matthew Lammi, MD
Category
Pulmonology
Title of Protocol
A Phase 3, Prospective, Multicenter, Double-Blind, Double-Dummy, Randomized,
Active-Controlled, Parallel Group, Group-Sequential, Adaptive, Event-Driven
Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75mg
vs. Macitentan 10mg in Patients with Pulmonary Arterial Hypertension,
Followed by an Open-Label Treatment Period with Macitentan 75mg
Brief Description
Additional Information
Recruitment Contact
#
504.568.3451
Principal Investigator
Matthew Lammi, MD
Category
Pulmonology
Title of Protocol
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety
and Efficacy of Antithrombotic and Additional Strategies in Hospitalized
Adults with COVID-19
Brief Description
Additional Information
Recruitment Contact
#
504.568.3451
Principal Investigator
Herbert Phelan, MD
Category
Burn
Title of Protocol
DeepView SnapShot Portable (DV-SSP): Device Training Study
Brief Description
Additional Information
Recruitment Contact
#
504.702.5171
Principal Investigator
Jeffrey Carter, MD
Category
Burn
Title of Protocol
A Pivotal Study to Assess the Safety and Effectiveness of NovoSorb®
Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn
Skin Injuries
Brief Description
Additional Information
Recruitment Contact
#
504.702.5171
Principal Investigator
Aaron Mammoser, MD
Category
Neurosurgery
Title of Protocol
GBM AGILE: An International, Seamless Phase II/III Response Adaptive Randomization
Platform Trial Designed to Evaluate Multiple Regimens in Newly Diagnosed
and Recurrent Glioblastoma.
Brief Description
Additional Information
Recruitment Contact
#
504.568.2507
Principal Investigator
Nassir Marrouche, MD
Category
Cardiology
Title of Protocol
EDORA: Effect of Dronedarone on Atrial Fibrosis Progression and Atrial
Fibrillation Recurrence Post-Ablation.
Brief Description
Additional Information
Recruitment Contact
#
504.988.6443
Principal Investigator
Maissaa Janbain, MD
Category
Hematology - Hemophilia
Title of Protocol
TRM-HA-301: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,
Phase III Study with a Long-Term, Open-Label Extension to Evaluate the
Efficacy and Safety of TRM-201 (Rofecoxib) in Patients with Hemophilic
Arthropathy
Brief Description
Additional Information
Recruitment Contact
#
504.988.3596
Principal Investigator
Cindy Leissinger, MD
Category
Hematology - Hemophilia
Title of Protocol
The Inhibitor ERAdication Trial (ERADICATE): The Phase III Multicenter,
Randomized Controlled Inhibitor Eradication Trial Comparing Eloctate Immune
Tolerance Induction (ITI) plus Emicizumab vs. Eloctate ITI alone to Eradicate
Inhibitor Formation in Severe Hemophilia A
Brief Description
Additional Information
Recruitment Contact
#
504.988.3596
Principal Investigator
Maissaa Janbain, MD
Category
Hematology - Hemophilia
Title of Protocol
Von Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of
Wilate Use in Von Willebrand Disease for Childbirth.
Brief Description
Additional Information
Recruitment Contact
#
504.988.3596
There are no Events to display.
